Targets › SV2A
15 programs from 15 companies in 18 trials: 7 Phase 3, 6 Phase 2, 3 Phase 1, 2 Phase 4; Neurology, Oncology, Psychiatry; next expected readout Dec 2026.
Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity)..; FUNCTION: (Microbial infection) Receptor for the C.botulinum neurotoxin type A2 (BoNT/A, botA); glycosylation is not essential but enhances the interaction. (UniProt, Q7L0J3)
Open in Phaseline: the race on SV2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| All India Institute of Medical Sciences, Jodhpur | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 4 | Seizures | Mar 2027 |
| Leiden University Medical Center | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 4 | Glioma | Jan 2028 |
| Beijing Tiantan Hospital | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Postoperative Seizures After Brain Tumor Surgery | Jan 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Down Syndrome | Dec 2027 |
| Waad Alkathiri | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Epilepsy | Dec 2028 |
| Shanghai East Hospital | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Suspected Stroke | Dec 2028 |
| UCB Biopharma SRL | Brivaracetam Synaptic vesicle glycoprotein 2A modulator | SV2A | Phase 3 | Childhood Absence Epilepsy; Epilepsy | Nov 2029 |
| Tata Memorial Centre | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 3 | Seizures | Jun 2031 |
| Johns Hopkins University | Levetiracetam (AGB101) Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Parkinson Disease Psychosis; Hippocampal Overactivity | Dec 2026 |
| University of California, San Diego | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Neonatal Seizure | Jul 2027 |
| Sunnybrook Health Sciences Centre | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Hippocampal Hyperactivation | Dec 2027 |
| Ayal A. Aizer, MD | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Seizures | Feb 2029 |
| Sohag University | Levetiracetam Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker | SV2A, Ion channels | Phase 2 | Generalized Convulsive Status Epilepticus | – |
| Yale University | [11C]UCB-J SV2A radiotracer for imaging synaptic density | SV2A | Phase 1 | Cannabis Use; HIV Associated Neurocognitive Disorder | Dec 2026 |
| Davidzon, Guido, M.D. | [11C]UCB-J SV2A positron emission tomography (PET) tracer | SV2A | Phase 1 | Schizophrenia | – |
Seizures (3) Epilepsy (2) Schizophrenia (1) Postoperative Seizures After Brain Tumor Surgery (1) Neonatal Seizure (1) Parkinson Disease Psychosis (1) Hippocampal Overactivity (1) Generalized Convulsive Status Epilepticus (1) Cannabis Use (1) HIV Associated Neurocognitive Disorder (1) Childhood Absence Epilepsy (1) Hippocampal Hyperactivation (1)
small molecule (15)
Davidzon, Guido, M.D. (1) Beijing Tiantan Hospital (1) University of California, San Diego (1) Johns Hopkins University (1) Waad Alkathiri (1) Sohag University (1) Ayal A. Aizer, MD (1) Yale University (1) UCB Biopharma SRL (1) Tata Memorial Centre (1) Sunnybrook Health Sciences Centre (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) All India Institute of Medical Sciences, Jodhpur (1) Leiden University Medical Center (1) Shanghai East Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.